Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537431 · ClinicalTrials.gov registry record · Phase 3
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)
A Phase 3 study, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 3
- Development phase
- 14
- Enrollment target
NCT02537431 is a Phase 3 study that has completed, run by Kyowa Kirin. The registered enrollment target is 14 participants.
The verdict
NCT02537431, a Phase 3 study, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14 participants
- Enrollment target
Study Summary
The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).
Interventions
- BIOLOGICAL burosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12-23 |
| Est. Completion | 2018-12-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02537431
The ClinicalTrials.gov registry entry for NCT02537431 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which burosumab is the first listed.
NCT02537431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02537431 about?
NCT02537431 is a clinical study titled "Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)". The primary objective of this study is to establish the effect of KRN23 treatment on improvement in XLH-associated osteomalacia as determined by osteoid volume (osteoid volume/bone volume, OV/BV).
What is the current status of trial NCT02537431?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14 participants. The study started on 2015-12-23. Estimated completion is 2018-12-13.
What interventions are being tested in trial NCT02537431?
The interventions under investigation include: burosumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02537431?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.